{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:17:39Z","timestamp":1786429059437,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK072517"],"award-info":[{"award-number":["DK072517"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK126070"],"award-info":[{"award-number":["DK126070"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007859","name":"University of Kansas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007859","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008510","name":"University of Maryland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.trsl.2023.10.005","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:21:13Z","timestamp":1698625273000},"page":"17-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment"],"prefix":"10.1016","volume":"265","author":[{"given":"Pattareeya","family":"Yottasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tifany","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth D.","family":"Chhetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-0199","authenticated-orcid":false,"given":"Onur","family":"Cil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9981","key":"10.1016\/j.trsl.2023.10.005_bib0001","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","article-title":"Autosomal dominant polycystic kidney disease: the changing face of clinical management","volume":"385","author":"Ong","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.trsl.2023.10.005_bib0002","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.trsl.2023.10.005_bib0003","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.trsl.2023.10.005_bib0004","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1681\/ASN.2021081125","article-title":"Protein kinase a downregulation delays the development and progression of polycystic kidney disease","volume":"33","author":"Wang","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.trsl.2023.10.005_bib0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MNH.0b013e3283621510","article-title":"Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease","volume":"22","author":"Devuyst","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.trsl.2023.10.005_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109703","article-title":"Targeting chloride transport in autosomal dominant polycystic kidney disease","volume":"73","author":"Jouret","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.trsl.2023.10.005_bib0007","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2147\/TCRM.S286952","article-title":"Safety profile of tolvaptan in the treatment of autosomal dominant polycystic kidney disease","volume":"17","author":"Bellos","year":"2021","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"10.1016\/j.trsl.2023.10.005_bib0008","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1681\/ASN.2006111218","article-title":"Identification of a forskolin-like molecule in human renal cysts","volume":"18","author":"Putnam","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.trsl.2023.10.005_bib0009","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11302-008-9102-6","article-title":"Purinergic signaling in the lumen of a normal nephron and in remodeled PKD encapsulated cysts","volume":"4","author":"Hovater","year":"2008","journal-title":"Purinergic Signal"},{"issue":"3","key":"10.1016\/j.trsl.2023.10.005_bib0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semnephrol.2018.02.005","article-title":"Vitamin D and calcimimetics in cardiovascular disease","volume":"38","author":"Lim","year":"2018","journal-title":"Semin Nephrol"},{"issue":"6","key":"10.1016\/j.trsl.2023.10.005_bib0011","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1517\/14656566.2013.777041","article-title":"Cinacalcet hydrochloride for the treatment of hyperparathyroidism","volume":"14","author":"Verheyen","year":"2013","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.trsl.2023.10.005_bib0012","doi-asserted-by":"crossref","first-page":"G240","DOI":"10.1152\/ajpgi.00500.2001","article-title":"Expression of calcium-sensing receptor in rat colonic epithelium: evidence for modulation of fluid secretion","volume":"283","author":"Cheng","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"25","key":"10.1016\/j.trsl.2023.10.005_bib0013","doi-asserted-by":"crossref","first-page":"9390","DOI":"10.1073\/pnas.0602996103","article-title":"Calcium-sensing receptor abrogates secretagogue- induced increases in intestinal net fluid secretion by enhancing cyclic nucleotide destruction","volume":"103","author":"Geibel","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"10.1016\/j.trsl.2023.10.005_bib0014","article-title":"Repurposing calcium-sensing receptor agonist cinacalcet for treatment of CFTR-mediated secretory diarrheas","volume":"6","author":"Oak","year":"2021","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.trsl.2023.10.005_bib0015","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1038\/s41598-018-23732-5","article-title":"Activation of Calcium-Sensing Receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells","volume":"8","author":"Di Mise","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.trsl.2023.10.005_bib0016","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1523-1755.2004.00967.x","article-title":"The relationship between cell proliferation, Cl- secretion, and renal cyst growth: a study using CFTR inhibitors","volume":"66","author":"Li","year":"2004","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.trsl.2023.10.005_bib0017","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1124\/molpharm.122.000542","article-title":"Lubiprostone is non-selective activator of cAMP-gated ion channels and Clc-2 has a minor role in its prosecretory effect in intestinal epithelial cells","volume":"102","author":"Oak","year":"2022","journal-title":"Mol Pharmacol"},{"issue":"8","key":"10.1016\/j.trsl.2023.10.005_bib0018","doi-asserted-by":"crossref","first-page":"F1176","DOI":"10.1152\/ajprenal.00130.2012","article-title":"Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth","volume":"303","author":"Li","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"10.1016\/j.trsl.2023.10.005_bib0019","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1681\/ASN.2007070828","article-title":"Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease","volume":"19","author":"Yang","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.trsl.2023.10.005_bib0020","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.kint.2023.01.026","article-title":"A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of autosomal dominant polycystic kidney disease","volume":"103","author":"Dagorn","year":"2023","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.trsl.2023.10.005_bib0021","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, Cl\u2212 secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin","volume":"301","author":"Reif","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trsl.2023.10.005_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.mcb.2019.05.005","article-title":"Generation of primary cells from ADPKD and normal human kidneys","volume":"153","author":"Wallace","year":"2019","journal-title":"Methods Cell Biol"},{"key":"10.1016\/j.trsl.2023.10.005_bib0023","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.mcb.2019.05.008","article-title":"In vitro cyst formation of ADPKD cells","volume":"153","author":"Sharma","year":"2019","journal-title":"Methods Cell Biol"},{"issue":"5","key":"10.1016\/j.trsl.2023.10.005_bib0024","doi-asserted-by":"crossref","first-page":"F815","DOI":"10.1152\/ajprenal.2001.280.5.F815","article-title":"The calcium-sensing receptor regulates calcium absorption in MDCK cells by inhibition of PMCA","volume":"280","author":"Blankenship","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trsl.2023.10.005_bib0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.coemr.2020.06.007","article-title":"Calcium-sensing receptor signaling - How human disease informs biology","volume":"16","author":"Gorvin","year":"2021","journal-title":"Curr Opin Endocr Metab Res"},{"issue":"7","key":"10.1016\/j.trsl.2023.10.005_bib0026","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1097\/01.ASN.0000016444.90348.50","article-title":"Epithelial-specific Cre\/lox recombination in the developing kidney and genitourinary tract","volume":"13","author":"Shao","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.trsl.2023.10.005_bib0027","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/hmg\/ddn039","article-title":"Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1","volume":"17","author":"Shibazaki","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.trsl.2023.10.005_bib0028","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.trsl.2023.10.005_bib0029","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1681\/ASN.2008090927","article-title":"Calcimimetic inhibits late-stage cyst growth in ADPKD","volume":"20","author":"Gattone","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.trsl.2023.10.005_bib0030","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/ndt\/gfn527","article-title":"Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease","volume":"24","author":"Wang","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.trsl.2023.10.005_bib0031","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1681\/ASN.2009050501","article-title":"Type II calcimimetics and polycystic kidney disease: unanswered questions","volume":"20","author":"Torres","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2023.10.005_bib0032","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1046\/j.1523-1755.63.s85.22.x","article-title":"Calcimimetic agents: review and perspectives","volume":"85","author":"Ure\u00f1a","year":"2003","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1016\/j.trsl.2023.10.005_bib0033","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1038\/s41598-021-89480-1","article-title":"Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease","volume":"11","author":"Nakatani","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.trsl.2023.10.005_bib0034","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"M\u00fcller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.trsl.2023.10.005_bib0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2215\/CJN.11260821","article-title":"Effects of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin V2 Receptor antagonist in ADPKD: a randomized crossover Trial","volume":"17","author":"Kramers","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.trsl.2023.10.005_bib0036","doi-asserted-by":"crossref","first-page":"e21874","DOI":"10.1096\/fj.202100774R","article-title":"Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease","volume":"35","author":"Di Mise","year":"2021","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.trsl.2023.10.005_bib0037","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/ki.1996.304","article-title":"The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro","volume":"50","author":"Davidow","year":"1996","journal-title":"Kidney Int"},{"issue":"15","key":"10.1016\/j.trsl.2023.10.005_bib0038","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1021\/jm200505e","article-title":"Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease","volume":"54","author":"Snyder","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2023.10.005_bib0039","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1172\/JCI0216112","article-title":"Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion","volume":"110","author":"Ma","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2023.10.005_bib0040","article-title":"Calcium-sensing receptor activator cinacalcet for treatment of cyclic nucleotide-mediated secretory diarrheas","author":"Chu","year":"2023","journal-title":"Transl Res"},{"issue":"6","key":"10.1016\/j.trsl.2023.10.005_bib0041","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2004.08.029","article-title":"Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200mg once daily","volume":"44","author":"Harris","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.trsl.2023.10.005_bib0042","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride","volume":"48","author":"Padhi","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.trsl.2023.10.005_bib0043","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/cpt.1846","article-title":"Does in vitro potency predict clinically efficacious concentrations?","volume":"108","author":"Jansson-L\u00f6fmark","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.trsl.2023.10.005_bib0044","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4196\/kjpp.2019.23.4.231","article-title":"Potency and plasma protein binding of drugs in vitro-a potentially misleading pair for predicting in vivo efficacious concentrations in humans","volume":"23","author":"Yim","year":"2019","journal-title":"Korean J Physiol Pharmacol"},{"key":"10.1016\/j.trsl.2023.10.005_bib0045","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021688s017lbl.pdf (Access date: 09.27.2023)."},{"issue":"2","key":"10.1016\/j.trsl.2023.10.005_bib0046","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.trsl.2023.10.005_bib0047","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.trsl.2023.10.005_bib0048","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"issue":"40","key":"10.1016\/j.trsl.2023.10.005_bib0049","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.2174\/1381612829666221027110656","article-title":"A systematic review and meta-analysis of efficacy and safety of calcimimetic agents in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease","volume":"28","author":"Liu","year":"2022","journal-title":"Curr Pharm Des"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524423001779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524423001779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:48:21Z","timestamp":1761828501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524423001779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":49,"alternative-id":["S1931524423001779"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2023.10.005","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2023.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}